QVA149A
Drug
Novartis Pharma AG
Total Payments
$60,241
Transactions
31
Doctors
6
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $17,056 | 8 | 4 |
| 2017 | $43,185 | 23 | 6 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $39,351 | 11 | 65.3% |
| Travel and Lodging | $13,049 | 9 | 21.7% |
| Unspecified | $6,667 | 1 | 11.1% |
| Food and Beverage | $1,175 | 10 | 2.0% |
Payments by Type
General
$53,574
30 transactions
Research
$6,667
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Publication support research related | Novartis Pharma AG | $6,667 | 1 |
Top Doctors Receiving Payments for QVA149A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Pulmonary Disease | San Antonio, TX | $19,356 | 4 |
| , MD | Critical Care Medicine | Ann Arbor, MI | $16,649 | 11 |
| , MD | Pulmonary Disease | Philadelphia, PA | $7,367 | 4 |
| , MD | Pulmonary Disease | Houston, TX | $6,903 | 5 |
| , MD | Pulmonary Disease | Chapel Hill, NC | $6,593 | 5 |
| , MD | Pulmonary Disease | Boston, MA | $3,373 | 2 |
Ad
Manufacturing Companies
- Novartis Pharma AG $60,241
Product Information
- Type Drug
- Total Payments $60,241
- Total Doctors 6
- Transactions 31
About QVA149A
QVA149A is a drug associated with $60,241 in payments to 6 healthcare providers, recorded across 31 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2017 to 2018. In 2018, $17,056 was paid across 8 transactions to 4 doctors.
The most common payment nature for QVA149A is "Consulting Fee" ($39,351, 65.3% of total).
QVA149A is associated with 1 research study, including "Publication support research related" ($6,667).